

HALOZYME THERAPEUTICS INC
Form 4
March 21, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
PATTON JOHN STUART

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS INC [HTI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
03/21/2007

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY RD., SUITE 17

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

SAN DIEGO, CA 92121

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/21/2007		S(1)		200	D	\$ 8.5
Common Stock	03/21/2007		S(1)		600	D	\$ 8.51
Common Stock	03/21/2007		S(1)		200	D	\$ 8.52
Common Stock	03/21/2007		S(1)		200	D	\$ 8.53

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock	03/21/2007	<u>S(1)</u>	800	D	\$ 8.54	335,471	D
Common Stock	03/21/2007	<u>S(1)</u>	4,000	D	\$ 8.55	331,471	D
Common Stock	03/21/2007	<u>S(1)</u>	1,300	D	\$ 8.56	330,171	D
Common Stock	03/21/2007	<u>S(1)</u>	2,400	D	\$ 8.57	327,771	D
Common Stock	03/21/2007	<u>S(1)</u>	2,500	D	\$ 8.58	325,271	D
Common Stock	03/21/2007	<u>S(1)</u>	1,500	D	\$ 8.59	323,771	D
Common Stock	03/21/2007	<u>S(1)</u>	3,800	D	\$ 8.6	319,971	D
Common Stock	03/21/2007	<u>S(1)</u>	1,700	D	\$ 8.61	318,271	D
Common Stock	03/21/2007	<u>S(1)</u>	100	D	\$ 8.62	318,171	D
Common Stock	03/21/2007	<u>S(1)</u>	900	D	\$ 8.63	317,271	D
Common Stock	03/21/2007	<u>S(1)</u>	200	D	\$ 8.64	317,071	D
Common Stock	03/21/2007	<u>S(1)</u>	500	D	\$ 8.65	316,571	D
Common Stock	03/21/2007	<u>S(1)</u>	1,100	D	\$ 8.66	315,471	D
Common Stock	03/21/2007	<u>S(1)</u>	700	D	\$ 8.67	314,771	D
Common Stock	03/21/2007	<u>S(1)</u>	500	D	\$ 8.68	314,271	D
Common Stock	03/21/2007	<u>S(1)</u>	1,000	D	\$ 8.69	313,271	D
Common Stock	03/21/2007	<u>S(1)</u>	500	D	\$ 8.7	312,771	D
Common Stock	03/21/2007	<u>S(1)</u>	200	D	\$ 8.71	312,571	D
Common Stock	03/21/2007	<u>S(1)</u>	100	D	\$ 8.75	312,471	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474
(9-02)

